Acute Myeloid Leukaemia (AML) Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Acute Myeloid Leukaemia (AML) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Acute Myeloid Leukaemia (AML)Follicular Lymphoma ( FL)
Tempus AI550 enrolled5 locationsNCT07154823
Recruiting
Phase 1Phase 2

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting
Phase 2Phase 3

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled17 locationsNCT06788756
Recruiting
Phase 1

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Not Applicable

Maintenance Venetoclax in AML Fit Patients

Acute Myeloid Leukaemia (AML)
Sohag University80 enrolled2 locationsNCT07244367
Recruiting
Not Applicable

Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukaemia (AML)
Rigshospitalet, Denmark15 enrolled1 locationNCT07062250
Recruiting
Not Applicable

Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia

Acute Lymphoblastic Leukemia ALLAcute Myeloid Leukaemia (AML)High Risk Leukaemia+1 more
University Of Perugia51 enrolled1 locationNCT06845592